https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
Background/aim We conducted a phase II study of neoadjuvant chemotherapy followed by extended field concurrent chemoradiotherapy in patients with cervical cancer with para-aortic node metastasis. Patients and methods Thirty-seven women with stage IB1-IVA cervical cancer were enrolled. Results The median age was 52 years. Thirty-four patients other than 3 progressive disease, proceeded to extended field concurrent chemoradiotherapy. The 3-year overall survival and progression-free survival rates were 70.1% and 48.5%, respecti
Like
Comment
Share
